Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 198

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 198
---
 Company.

“Company” means Repare Therapeutics Inc.

“Company Outstanding Shares” means the total number of issued and outstanding Common Shares at the Effective Time, on a
partially diluted basis taking into account the Common Shares issuable upon exercise of all Options and upon settlement of all RSUs.

“Company Public Documents” has the meaning ascribed thereto in Section 1.1 of the Agreement.

“Consideration” means, per Common Share, the aggregate cash amount payable by the Company pursuant to the Distribution plus
one CVR issuable by the Purchaser.

“Contemplated Transactions” has the meaning ascribed thereto in Section 1.1 of
the Agreement.

“Contract” means any agreement, indenture, contract, lease, deed of trust, license, option, instrument,
arrangement, undertaking or other commitment, whether written or oral.

“Convertible Securities” has the meaning
ascribed thereto in Section 1.1 of the Agreement.

“Court” means the Superior Court of Québec, Commercial
Division.

“CRA” has the meaning ascribed thereto in “Certain Canadian Federal Income Tax Considerations of the Arrangement” and “Certain Canadian Federal Income Tax Considerations of the Liquidation,” as applicable.

126

“CVR” means a contingent value right, which shall represent the right to
receive potential payments, in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement.

“CVR Agreement” means the contingent value rights agreement to be entered into on or prior to the Effective Date by Parent,
Purchaser and the Rights Agent, in substantially the form attached as Schedule F to the Agreement.

“CVR Payment Amount” has the meaning scribed thereto in Section 1.1 of the CVR Agreement.

“CVR Payment Date” has the
meaning ascribed thereto in Section 1.1 of the CVR Agreement.

“Depositary” means Broadridge Corporate Issuer
Solutions, LLC.

“Disclosure Letter” means the disclosure letter executed by the Company and delivered to the Purchaser
on November 14, 2025, in connection with the execution of the Agreement.

“Discontinuance” has the meaning
ascribed thereto in Section 1.1 of the Agreement.

“Dissent Rights” means the rights of dissent in respect of the
Arrangement described in the Plan of Arrangement.

“Dissent Shares” means the Common Shares held by a